Prime Medicine Offering Expands Share Base — Robert Nelsen Reports An 8.4% Beneficial Stake

The reporting shareholders said they made no common-stock transactions during the preceding 60 days.

Share
Prime Medicine Offering Expands Share Base — Robert Nelsen Reports An 8.4% Beneficial Stake

Prime Medicine, which develops genetic medicines that rewrite DNA, sold 41,071,428 shares Thursday, expanding the share base behind shareholder Robert Nelsen's reported 8.4% beneficial stake. His amended SEC ownership disclosure filed Friday counted 18,642,036 shares, including shared holdings and vested options.

More Shares In The Denominator

The ownership calculation used 222,992,833 common shares before adding Nelsen's options. That base comprised 181,921,405 shares outstanding on October 31 and the shares Prime Medicine sold in Thursday's underwritten offering.

For Nelsen's percentage, the calculation also included 139,062 shares he could obtain by exercising vested options. Beneficial ownership counts shares a person can direct or obtain, including holdings subject to shared authority.

The reporting shareholders said they made no common-stock transactions during the preceding 60 days. The company-issued shares enlarged the denominator used to measure their ownership.

ARCH Holdings Carry Shared Authority

Nelsen's total included shared voting authority over 18,486,894 shares, plus 16,080 shares belonging to him and related trusts and the vested options.

The shares held by the ARCH funds were divided among ARCH Venture Fund X and ARCH Venture Fund X Overage, each with 6,128,297 shares, and ARCH Venture Fund XII, with 6,230,300 shares.

Overlapping general partners and investment committee members meant affiliated reporting persons could be deemed beneficial owners of the shared holdings. The joint report included the funds, affiliated ARCH Venture Partners entities and investment committee members Keith Crandell, Kristina Burow and Steven Gillis. The reporting persons other than Nelsen each reported 8.3% beneficial ownership covering 18,486,894 shares.

The original joint ownership statement was filed on February 22, 2024.

Genetic Medicines And Licensing Revenue

Prime Medicine's internally owned programs target liver diseases, including Wilson disease and alpha-1 antitrypsin deficiency. Its work also includes cystic fibrosis research and a clinical program for chronic granulomatous disease.

The company combines its own treatment development with research and licensing collaborations. Bristol-Myers Squibb licenses its Prime Editing technology to develop treatments using immune cells edited outside the body; that collaboration, signed in September 2024, generated a $55 million upfront payment.

The Cystic Fibrosis Foundation supplies development funding for Prime Medicine's cystic fibrosis work. Prime Medicine had a market value of $706 million as of 4:12 p.m. ET Friday.

Most of Nelsen's reported beneficial stake rests on shared authority over the ARCH funds' shares; his own and related trusts' shares and vested options account for the rest.

Sources

More on Prime Medicine

All Prime Medicine (PRME) coverage →